

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 1 and 2 of 2020**

Statements of Principles Nos. 1 and 2 of 2020 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 20 December 2019. The day of commencement as specified in each of these Instruments is 27 January 2020.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

7 January 2020

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REVOCATIONS** |
|  |  |  |  |
| 1 & 2/2020 | Kaposi sarcoma | 27/01/2020 | C46 |
|  |  |  |  |

Note:

The investigation concerning 'Kaposi's sarcoma' has resulted in the determination of Statements of Principles concerning Kaposi sarcoma.

| **SUMMARY OF CHANGES** |
| --- |
| 1 & 2 of 2020 | Kaposi sarcoma | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 8 May 2018 concerning *Kaposi's sarcoma* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 1/2020)**** adopting the latest revised Instrument format, which commenced in 2015;
* changing the title of the Instrument to 'Kaposi sarcoma';
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'Kaposi sarcoma' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'human herpesvirus type 8';
* revising the factor in subsection 9(2) concerning 'human immunodeficiency virus';
* new factor in subsection 9(3) concerning 'non-Hodgkin lymphoma or chronic lymphocytic leukaemia/small lymphocytic lymphoma';
* new factor in subsection 9(4) concerning 'chronic renal failure';
* new factor in subsection 9(5) concerning 'autoimmune disease';
* new factor in subsection 9(6) concerning 'diabetes mellitus';
* new factor in subsection 9(7) concerning 'lymphoedema';
* revising the factor in subsection 9(8) concerning 'solid organ, stem cell or bone marrow transplantation';
* revising the factor in subsection 9(9) concerning 'being treated with an immunosuppressive drug';
* new factor in subsection 9(10) concerning 'being treated with an angiotensin converting enzyme inhibitor';
* deleting the factors concerning 'treatment with azathioprine, cyclophosphamide, methotrexate or mycophenolate' and 'treatment with high dose corticosteroid therapy', as they are now subsumed by the factor in subsection 9(9) concerning 'being treated with an immunosuppressive drug';
* new definitions of 'chronic renal failure', 'immunosuppressive drug', 'MRCA', 'specified list of autoimmune diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'high dose corticosteroid therapy'.

***For BoP SoP (Instrument No. 2/2020)**** adopting the latest revised Instrument format, which commenced in 2015;
* changing the title of the Instrument to 'Kaposi sarcoma';
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'Kaposi sarcoma' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'human herpesvirus type 8';
* revising the factor in subsection 9(2) concerning 'human immunodeficiency virus';
* new factor in subsection 9(3) concerning 'non-Hodgkin lymphoma or chronic lymphocytic leukaemia/small lymphocytic lymphoma';
* revising the factor in subsection 9(4) concerning 'solid organ, stem cell or bone marrow transplantation';
* revising the factor in subsection 9(5) concerning 'being treated with an immunosuppressive drug';
* new factor in subsection 9(6) concerning 'being treated with an angiotensin converting enzyme inhibitor';
* deleting the factor concerning 'treatment with azathioprine, cyclophosphamide, methotrexate or mycophenolate', as it is now subsumed by the factor in subsection 9(5) concerning 'being treated with an immunosuppressive drug';
* new definitions of 'immunosuppressive drug', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'high dose corticosteroid therapy'.

**The determining of these Instruments finalises the investigation in relation to *Kaposi's sarcoma* as advertised in the Government Notices Gazette of 8 May 2018.** |